Systematic treatment in gastric cancer patients with overt bleeding: A propensity score matching analysis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

354

Figures (1-2)

Tables (1-5)

Sum=503

Publishing Process of This Article

Item

Count

Browse

Download

Sum=87

Sep 24, 2024 (publication date) through Oct 4, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Clin Oncol. Sep 24, 2024; 15(9): 1177-1187
Published online Sep 24, 2024. doi: 10.5306/wjco.v15.i9.1177

Table 3 Therapeutic regimen and best response in patients after propensity score matching, n (%)

Characteristics	Total (n = 93)	Patients with OBBT (n = 32)	Patients without OBBT (n = 61)	P value
Therapeutic regimen
Chemotriplet regimen	36 (38.7)	6 (18.8)	30 (49.2)	0.006
¹Chemodoublet-based regimen	54 (58.1)	24 (75.0)	30 (49.2)
²Monotherapy	3 (3.2)	2 (6.3)	1 (1.6)
Radiographic best response
CR or PR	21 (22.6)	11 (34.4)	10 (16.4)	0.157
SD/no CR or no PR	62 (66.7)	18 (56.2)	44 (72.1)
PD	7 (7.5)	3 (9.4)	4 (6.6)
NA	3 (3.2)	0	3 (4.9)
Radical surgery after systematic treatment
Yes	14 (15.1)	5 (15.6)	9 (14.8)	0.911
No	79 (84.9)	27 (84.4)	52 (85.2)

¹Regimen included a chemodoublet regimen, a chemodoublet plus targeted therapy regimen, and a chemodoublet plus immune checkpoints inhibitor regimen.

²Fluorouracil monotherapy or immune check points inhibitor monotherapy.

OBBT: Overt bleeding before treatment; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NA: Not available.

Citation: Yao YH, Zhang H, Xiao Y, Liu ZT, Shi YY, Yu JY, Li Q, Cao BS. Systematic treatment in gastric cancer patients with overt bleeding: A propensity score matching analysis. World J Clin Oncol 2024; 15(9): 1177-1187
URL: https://www.wjgnet.com/2218-4333/full/v15/i9/1177.htm
DOI: https://dx.doi.org/10.5306/wjco.v15.i9.1177